This edition of GF Brief covers a Phase 2a trial for an experimental celiac treatment, an updated global prevalence estimate, and new research linking celiac disease to musculoskeletal conditions. It also tracks a Brazilian Superior Court hearing that could set a binding precedent for gluten warning labels, new UK school guidance for students with celiac disease, and recent gluten-related recalls across Canada, the UK, Ireland, and Spain.
Teva’s celiac drug shows early promise.
A single dose of experimental TEV ’408 protected against intestinal damage during six weeks of daily gluten exposure in a 50-person Phase 2a trial. Intestinal inflammation rose far less in the treatment group than with placebo, and participants also reported fewer gastrointestinal symptoms.
TEV ’408 remains investigational and does not replace a strict gluten-free diet.
Sources: Teva Pharmaceutical Industries; Celiac Disease Foundation, September 2026.
Celiac disease may be nearly twice as common in children as adults.
A global meta-analysis of 87 studies involving nearly 400,000 people found celiac prevalence was almost twice as high in children and 50% higher in females. Overall, about 1 in 70 people had positive celiac blood tests, while 1 in 120 had biopsy-confirmed celiac disease.
Source: Karimzadhagh et al., Gastroenterology, August 2026.
Study finds a two-way link between celiac disease and musculoskeletal conditions.
People with celiac disease had a 68% higher overall musculoskeletal burden during follow-up, while greater musculoskeletal burden was also strongly associated with celiac disease. Significant links included osteoporosis, osteoarthritis, rheumatoid arthritis, lupus, spondylosis, and enthesopathies or synovial disorders. The findings show association, not causation.
Source: Cai et al., Clinical Rheumatology, August 2026.
Brazilian court will revisit what gluten warnings must say.
Brazil’s Superior Court of Justice will hold a September 23 public hearing on whether “contains gluten” is enough on food labels—or whether products must also warn that gluten is harmful to people with celiac disease. The case could establish a binding legal precedent.
Source: Superior Court of Justice of Brazil, September 2026.
England strengthens school guidance for students with celiac disease.
New statutory guidance that took effect September 1 specifically recognizes celiac disease and calls for staff training, gluten cross-contact controls, and clear communication with families about school meals. Celiac disease is managed through schools’ arrangements for supporting students with medical conditions.
Sources: Department for Education; Coeliac UK, August–September 2026.
Gluten-related recalls:
Canada recalled Kim Phat Seafood Medley for undeclared wheat, while the UK recalled Iceland Daily Bakery 4 Sub Rolls for undeclared barley and Waitrose Rhubarb Crumble for undeclared oats/gluten. Ireland recalled specific Lidl Crownfield bars over undeclared gluten-containing cereals. In Spain, specific sauces sold under the Vulpi and Dumt’s brands and marketed as gluten-free were found to contain undeclared gluten.
Sources: CFIA; UK FSA; FSAI; AESAN, August–September 2026.
The Gluten-Free Brief is a twice-monthly informational news roundup from the Gluten-Free Food Program. It is provided for educational purposes and does not replace medical advice from qualified professionals. Inclusion of any product, brand, or organization does not imply endorsement by GFFP. Previous editions can be found here and on our LinkedIn, Instagram, and TikTok. Stay informed. Stay safe.
